RxDoctor Payments Data

Ian Singer, DO

Family Medicine · Fort Lauderdale, FLNPI 1689237919

Payments from drug & device makers

$1,647in general payments, 2019–2025

Across 54 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$350
  • Novo Nordisk$297
  • Heartflow, Inc.$225
  • Davol Inc.$162
  • Intuitive Surgical$110
  • Lilly USA, LLC$100
  • plus $403 from 11 others

What the payments were for

  • Food & beverage$1,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$114,876
Medicare patients
368
Services billed
1,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$87,331
MounjaroTirzepatide67$82,990
EliquisApixaban45$62,762
FarxigaDapagliflozin Propanediol39$43,045
XareltoRivaroxaban30$40,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,393
JardianceEmpagliflozin24$24,812
RybelsusSemaglutide13$24,262
DescovyEmtricitabine/Tenofov Alafenam11$22,495
MyrbetriqMirabegron13$12,931
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,747
Restasis MultidoseCyclosporine11$6,712
Rosuvastatin Calcium345$5,371
PremarinEstrogens, Conjugated11$4,866
Fluticasone Propionate302$4,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$297$111,59279 claims
Lilly USA, LLCMounjaro$100$82,99067 claims
GSKTrelegy Ellipta$13$30,39333 claims
Astellas Pharma US IncMyrbetriq$19$12,93113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →